Grants and Contributions

The CIHR Institute of Cancer Research (CIHR-ICR) has a mandate to support research that reduces the burden of cancer on individuals and families through prevention strategies, screening, diagnosis, effective treatments, psycho-social support systems, and palliation.

This PA will fund Breast Cancer research in the following priority areas:

• General Breast Cancer Research
o research that supports CIHR-ICR’s mandate in the area of Breast Cancer
• Breast Cancer Prevention and/or Early Detection of Breast Cancer
o research that prevents the onset of breast cancer (lowers cancer risk) and/or reduces the severity of the disease through early detection when it is at its most treatable.
• Breast Cancer Survivorship
o research that mitigates the challenges experienced along the breast cancer survivorship journey and improves the health outcomes for breast cancer survivors of all ages from the time of their cancer diagnosis until the time of their death or entry into end-of-life care.
o specifically in the areas of:
¿ Late & Long-Term Effects
¿ Survivors’ Experiences & Outcomes
¿ Models of Care
o This PA will not fund research focused on improving end-of-life care.

• This PA supports research that creates new knowledge and/or moves it into practice in the health system, communities, workplaces, and in the daily lives of Canadians.

The specific objective of this funding opportunity is to:

• Catalyze and support research efforts of Canadian researchers to use the available CLSA data in order to better understand how biological, medical, psychological, social, lifestyle and/or economic aspects of people’s lives have an impact on both maintaining health and the development of disease and disability as people age.

This award was established to recognize the excellence of cancer research being conducted in Canada. This award will be given annually to the highest-ranking Early Career Researchers in the Project Grant competition that fall within the CIHR Institute of Cancer Research (CIHR-ICR) mandate:

• ICR has a mandate to support research that reduces the burden of cancer on individuals and families through prevention strategies, screening, diagnosis, effective treatments, psycho-social support systems, and palliation.

The CIHR Institute of Cancer Research (CIHR-ICR) has a mandate to support research that reduces the burden of cancer on individuals and families through prevention strategies, screening, diagnosis, effective treatments, psycho-social support systems, and palliation.

This PA will fund Cancer research in the following priority areas:

• Cancer Prevention and/or Early Detection of Cancer
o research that prevents the onset of cancer (lowers cancer risk) and/or reduces the severity of the disease through early detection when it is at its most treatable.
• Cancer Survivorship
o research that mitigates the challenges experienced along the cancer survivorship journey and improves the health outcomes for cancer survivors of all ages from the time of their cancer diagnosis until the time of their death or entry into end-of-life care.
o specifically in the areas of:
¿ Late & Long-Term Effects
¿ Survivors’ Experiences & Outcomes
¿ Models of Care
o This PA will not fund research focused on improving end-of-life care.

• This PA supports research that creates new knowledge and/or moves it into practice in the health system, communities, workplaces, and in the daily lives of Canadians.

The CIHR Institute of Cancer Research (CIHR-ICR) has a mandate to support research that reduces the burden of cancer on individuals and families through prevention strategies, screening, diagnosis, effective treatments, psycho-social support systems, and palliation.

This PA will fund Cancer research in the following priority areas:

• Cancer Prevention and/or Early Detection of Cancer
o research that prevents the onset of cancer (lowers cancer risk) and/or reduces the severity of the disease through early detection when it is at its most treatable.
• Cancer Survivorship
o research that mitigates the challenges experienced along the cancer survivorship journey and improves the health outcomes for cancer survivors of all ages from the time of their cancer diagnosis until the time of their death or entry into end-of-life care.
o specifically in the areas of:
¿ Late & Long-Term Effects
¿ Survivors’ Experiences & Outcomes
¿ Models of Care
o This PA will not fund research focused on improving end-of-life care.

• This PA supports research that creates new knowledge and/or moves it into practice in the health system, communities, workplaces, and in the daily lives of Canadians.

The specific objective of this funding opportunity is to:

· Create new knowledge through the analysis of existing Canadian-based cohorts, data platforms and/or administrative datasets specific to human development, child, and/or youth health and in turn improve health outcomes and inform population and public health decision-making.

The specific objective of this funding opportunity is to:

· Create new knowledge through the analysis of existing Canadian-based cohorts, data platforms and/or administrative datasets specific to human development, child, and/or youth health and in turn improve health outcomes and inform population and public health decision-making.

The CIHR HIV/AIDS and Sexually Transmitted and Blood-Borne Infections (STBBI) Research Initiative, under the leadership of the CIHR Institute of Infection and Immunity (CIHR-III), defines STBBI as infections that are transmitted primarily through exchange of body fluids during sexual contact and/or through blood, and supports projects with a primary focus on STBBI of public health relevance, including but not limited to HIV/AIDS, chlamydia, gonorrhea, syphilis, hepatitis B, hepatitis C and human papillomavirus. This funding is provided across all CIHR research themes: biomedical research, clinical research, health services research and social, cultural, environmental and population health research.
Research that focuses on key populations disproportionately affected by HIV/AIDS and STBBI is highly encouraged.
In alignment with CIHR's commitment to equity, diversity and inclusion (EDI) in the research system, the Research Initiative champions EDI as a means to support excellence in research, training and knowledge mobilization. Therefore, we encourage people from diverse backgrounds, including groups underrepresented in science such as women and racial and ethnic minorities, to apply.
This Priority Announcement will prioritize funding for research on HIV/AIDS and/or STBBI aligned with the CIHR HIV/AIDS Research Initiative: Strategic Plan (2022-2027) in the following research areas:
• Improving health equity by advancing research to understand and address determinants of health, new models of care, or sexual and reproductive health for people living with or at risk of HIV/AIDS and STBBI; or
• Accelerating discovery and innovation by advancing research on innovative technologies for testing and surveillance, interactions among infections and co-morbidities, or design and development of next-generation interventions.

The CIHR HIV/AIDS and Sexually Transmitted and Blood-Borne Infections (STBBI) Research Initiative, under the leadership of the CIHR Institute of Infection and Immunity (CIHR-III), defines STBBI as infections that are transmitted primarily through exchange of body fluids during sexual contact and/or through blood, and supports projects with a primary focus on STBBI of public health relevance, including but not limited to HIV/AIDS, chlamydia, gonorrhea, syphilis, hepatitis B, hepatitis C and human papillomavirus. This funding is provided across all CIHR research themes: biomedical research, clinical research, health services research and social, cultural, environmental and population health research.
Research that focuses on key populations disproportionately affected by HIV/AIDS and STBBI is highly encouraged.
In alignment with CIHR's commitment to equity, diversity and inclusion (EDI) in the research system, the Research Initiative champions EDI as a means to support excellence in research, training and knowledge mobilization. Therefore, we encourage people from diverse backgrounds, including groups underrepresented in science such as women and racial and ethnic minorities, to apply.
This Priority Announcement will prioritize funding for research on HIV/AIDS and/or STBBI aligned with the CIHR HIV/AIDS Research Initiative: Strategic Plan (2022-2027) in the following research areas:
• Improving health equity by advancing research to understand and address determinants of health, new models of care, or sexual and reproductive health for people living with or at risk of HIV/AIDS and STBBI; or
• Accelerating discovery and innovation by advancing research on innovative technologies for testing and surveillance, interactions among infections and co-morbidities, or design and development of next-generation interventions.

CIHR is committed to leverage the power of research to accelerate global health equity for all. The CIHR Framework for Action on Global Health Research 2021-2026 recognizes that CIHR must work globally because today’s most pressing health problems, and many of the most effective strategies to prevent, contain, and address them, are global. In alignment with this Framework, this priority announcement aims to grow global health research capacity and excellence.
Funding will be provided for applications that have a primary focus on global health research (as per CIHR’s definition) and that are relevant to one of the mandates below:
• Centre for Research on Pandemic Preparedness and Health Emergencies (CRPPHE)
• Institute of Population and Public Health (IPPH)